학술논문

Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors
Document Type
Report
Source
Cancer. April 1, 2015, Vol. 121 Issue 7, p1056, 8 p.
Subject
United States
Language
English
ISSN
0008-543X